List of Excipients in Branded Drug MUCINEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ATLANTIC BIOLOGICAS CORP	MUCINEX	guaifenesin	17856-0008	ALUMINUM OXIDE
ATLANTIC BIOLOGICAS CORP	MUCINEX	guaifenesin	17856-0008	CARBOMER HOMOPOLYMER TYPE B
ATLANTIC BIOLOGICAS CORP	MUCINEX	guaifenesin	17856-0008	CELLULOSE, MICROCRYSTALLINE

Generic Drugs Containing MUCINEX

Company	Ingredient	NDC	Excipient
Reckitt Benckiser LLC	fexofenadine hydrochloride	63824-926	CROSCARMELLOSE SODIUM
Reckitt Benckiser LLC	fexofenadine hydrochloride	63824-926	FD&C RED NO. 40
Reckitt Benckiser LLC	fexofenadine hydrochloride	63824-926	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in MUCINEX?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	FD&C RED NO. 40

Mucinex Excipient Strategy and Commercial Opportunities

Last updated: August 20, 2026

Mucinex is a guaifenesin-led over-the-counter respiratory brand whose commercial value depends more on dosage-form engineering, consumer recognition, and retail execution than on active-ingredient exclusivity. The strongest excipient opportunities are extended-release matrix systems, moisture and stability control, taste masking, swallowability improvements, sugar-free liquids, and age-specific formulations.

What active ingredients and dosage forms does Mucinex use?

Mucinex products are built around guaifenesin, an expectorant used to loosen and thin bronchial mucus. Combination products add dextromethorphan, acetaminophen, pseudoephedrine, or other active ingredients depending on the product.

Product segment	Principal active ingredient or ingredients	Typical dosage form	Primary excipient challenge
Mucinex Extended-Release	Guaifenesin	Bilayer or matrix tablet	Twelve-hour release and tablet size
Mucinex DM	Guaifenesin and dextromethorphan	Extended-release tablet	Release separation and chemical stability
Mucinex Maximum Strength	Higher-dose guaifenesin	Extended-release tablet	High drug loading and swallowability
Mucinex Fast-Max	Combination cough, cold and flu actives	Liquid, capsule, or tablet	Taste, solubility, compatibility, and dosing accuracy
Children’s Mucinex	Guaifenesin, with or without dextromethorphan	Liquid, chewable, or mini-tablet	Taste masking and pediatric dosing
Mucinex Free From Sugar	Guaifenesin or combination actives	Oral liquid	Sweetener system, viscosity, and preservative control

Guaifenesin is permitted as an OTC expectorant under the FDA’s cough, cold, allergy, bronchodilator, and antiasthmatic drug framework. Dextromethorphan is regulated as an OTC antitussive under the same broader regulatory category.[1]

The Mucinex brand is associated primarily with extended-release guaifenesin tablets. That dosage form creates a larger technical barrier than an immediate-release guaifenesin tablet because the manufacturer must control dissolution over approximately 12 hours while maintaining dose uniformity and mechanical integrity.

Which excipients are most important in Mucinex extended-release tablets?

The core excipient strategy is a hydrophilic matrix combined with compression aids, disintegrants, glidants, lubricants, and film-coating materials. Public product labels identify inactive ingredients, but they do not disclose the full formulation architecture, processing conditions, polymer grade, or manufacturing controls.[2]

Hydrophilic release-control polymers

Hypromellose is a likely central polymer class for extended-release guaifenesin tablets. When exposed to gastrointestinal fluid, hypromellose hydrates and forms a gel layer. Drug release is controlled through gel erosion, diffusion, or a combination of both.

Commercial opportunities include:

• Low- and medium-viscosity hypromellose grades for release adjustment.
• High-viscosity hypromellose for stronger release control.
• Polyethylene oxide or carbomer systems for alternative matrix designs.
• Polymer blends that reduce sensitivity to compression force.
• Direct-compression excipients that support high drug loading.

The commercial value of a polymer supplier increases when its material delivers consistent release across different tablet hardness levels, production speeds, and storage conditions.

Compression and high-drug-load excipients

Guaifenesin has a relatively high dose compared with many prescription solid-dose products. A 600 mg or 1,200 mg dose places pressure on tablet size, friability, ejection force, and patient acceptability.

Relevant excipient classes include:

• Microcrystalline cellulose for compactibility.
• Coprocessed cellulose systems for flow and compression.
• Povidone or other binders for granule strength.
• Colloidal silicon dioxide for flow improvement.
• Magnesium stearate or alternative lubricants for ejection.
• Sodium starch glycolate or related disintegrants where rapid surface breakup is required.

A formulation must balance opposing functions. Excessive lubricant can reduce wettability and slow dissolution. Excessive disintegrant can weaken an extended-release matrix. High polymer loading can increase tablet size and reduce patient adherence.

Film coatings

Mucinex tablets use a recognizable colored and textured coating. The coating contributes to product identification, swallowability, moisture protection, and mechanical durability.

Potential coating components include:

• Hypromellose or polyvinyl alcohol as a film former.
• Polyethylene glycol as a plasticizer.
• Titanium dioxide or approved colorants for opacity and color.
• Talc or silica for anti-tacking and processing control.
• Carnauba wax or other surface-modifying materials for gloss and tactile properties.

For a branded OTC product, coating appearance has commercial importance. A generic tablet that matches the active ingredient and dissolution profile may still compete less effectively if it has inferior color consistency, tablet marking, surface smoothness, or package recognition.

What excipient strategies create the strongest commercial opportunities?

1. Smaller extended-release tablets

Tablet size is a significant commercial constraint for guaifenesin products. A smaller tablet can improve adherence, particularly for older adults and consumers taking several cold medications.

Development opportunities include:

• Higher-density excipient systems.
• Multiparticulate compressed tablets.
• More efficient polymer matrices.
• Bilayer designs that separate immediate-release and extended-release fractions.
• Granulation processes that improve flow without increasing tablet volume.

The preferred platform would preserve 12-hour dissolution while reducing tablet dimensions and maintaining acceptable hardness.

2. Taste-masked liquids and chewables

Liquid products create opportunities for suppliers of sweeteners, flavors, viscosity modifiers, and taste-masking systems. Guaifenesin and dextromethorphan combinations can produce bitterness, throat irritation, or an unpleasant aftertaste.

Relevant technologies include:

• Ion-exchange resin complexes.
• Lipid or polymeric microencapsulation.
• Flavor systems designed for rapid bitterness suppression.
• Sucralose, acesulfame potassium, steviol glycosides, or polyol combinations.
• Structured suspensions that prevent settling without excessive mouth coating.

Pediatric products require more than a strong flavor. The formulation must provide dose uniformity after shaking, stable viscosity across temperature ranges, accurate dosing with the supplied device, and acceptable preservative performance.

3. Sugar-free and low-calorie formulations

Sugar-free respiratory liquids address consumers managing diabetes, calorie intake, dental health, or dietary restrictions. The technical challenge is that sucrose contributes sweetness, viscosity, body, and mouthfeel.

Commercially relevant substitutes include:

• Sorbitol or glycerin for body and sweetness.
• Propylene glycol as a solvent and humectant.
• Sucralose or acesulfame potassium for high-intensity sweetness.
• Xanthan gum, cellulose derivatives, or carbomer for viscosity.
• Benzoate or sorbate systems for preservation, where compatible with pH.

A sugar-free platform can support line extensions without changing the active ingredient or therapeutic positioning.

4. Moisture-control systems

Guaifenesin tablets and combination products require protection from moisture, especially when the dosage form contains hygroscopic excipients or moisture-sensitive actives.

Opportunities include:

• High-barrier blister films.
• Induction-sealed HDPE bottles.
• Desiccant-integrated closures.
• Low-moisture excipient grades.
• Moisture-resistant film coatings.
• Packaging optimized for bathroom storage and repeated opening.

Packaging and excipient decisions should be evaluated together. A formulation that performs well in a laboratory bottle may show dissolution drift after repeated consumer exposure to humidity.

5. Combination-product compatibility

Mucinex combination products present a more complex excipient problem than single-ingredient guaifenesin tablets. Dextromethorphan, acetaminophen, and decongestants can have different solubility, stability, and release requirements.

A technically differentiated platform could use:

• Separate granules for each active ingredient.
• Bilayer or multilayer tablets.
• Coated particles for one component.
• pH-modified microenvironments.
• Distinct release-control polymers for expectorant and antitussive fractions.

This approach can reduce chemical interaction and improve dissolution control. It also creates process and know-how barriers that are harder to reproduce from a simple inactive-ingredient list.

What formulations are protected by Mucinex intellectual property?

The active ingredient, guaifenesin, is an old OTC drug and does not provide meaningful composition-of-matter exclusivity for Mucinex. The principal protectable assets are:

• Extended-release matrix architecture.
• Polymer selection and viscosity grade.
• Granulation and compression conditions.
• Bilayer or multiparticulate designs.
• Tablet coating and visual appearance.
• Combination-product release profiles.
• Taste-masking systems.
• Packaging and moisture-control configurations.
• Trademarks, trade dress, and brand recognition.

Mucinex products may have had historical formulation patents or regulatory exclusivity associated with specific products. Patent rights must be assessed at the product and jurisdiction level because different Mucinex formulations can have different regulatory sponsors, labels, and legal records.

Is Mucinex listed in the Orange Book?

The Orange Book primarily covers approved prescription and certain approved nonprescription drug applications. Many OTC monograph products do not rely on an NDA-based Orange Book patent estate in the same way as prescription drugs.[3]

For Mucinex, the commercially important distinction is between:

1. OTC monograph-compliant products, which generally do not depend on a conventional NDA patent listing for market access; and
2. product-specific approved applications or formulations, which may have application-specific regulatory and patent records.

The Mucinex trademark and packaging identity can remain valuable after formulation patents expire. A generic manufacturer may enter with a therapeutically equivalent guaifenesin product while avoiding Mucinex branding and trade dress.

When does Mucinex lose exclusivity?

Mucinex has no single exclusivity-loss date because the brand covers multiple formulations and combinations. The original guaifenesin active ingredient is long off patent. Competitive entry is therefore governed by formulation development, OTC regulatory status, trademark restrictions, manufacturing economics, and retail access.

Exclusivity layer	Current commercial relevance
Guaifenesin composition of matter	Expired or unavailable as a practical barrier
Standard immediate-release guaifenesin	Low technical barrier
Extended-release formulation	Moderate formulation and process barrier
Combination products	Moderate compatibility and release barrier
Mucinex trademark	Ongoing while maintained and used
Packaging and trade dress	Ongoing, subject to non-infringement
OTC regulatory pathway	Determines market-entry requirements
Retail distribution	Important commercial barrier

A generic manufacturer can usually target the active ingredient without copying Mucinex branding. The more difficult target is the extended-release product, particularly where the reference product uses a high-dose tablet with a narrow dissolution profile.

What generic entry risks exist for Mucinex?

Generic entry risk is highest for basic guaifenesin products and lower for differentiated extended-release and combination products.

Immediate-release products

Immediate-release guaifenesin tablets and liquids have limited formulation complexity. Competition can focus on:

• Lower-cost excipients.
• Private-label manufacturing.
• Retailer-owned brands.
• Large-volume bottle formats.
• Simplified flavor systems.

These products are vulnerable to price competition and retailer substitution.

Extended-release tablets

Extended-release products have higher technical risk because a generic must demonstrate appropriate release performance and comply with applicable FDA requirements. The key development variables are:

• Polymer hydration.
• Tablet porosity.
• Compression force.
• Drug loading.
• Dissolution method.
• Stability under humidity.
• Dose uniformity.
• Tablet dimensions.

A Paragraph IV challenge is legally relevant only where an applicable listed patent exists. For an OTC monograph product, the more likely route is development of a compliant alternative product rather than a conventional Paragraph IV challenge to a listed NDA patent.[3,4]

Brand substitution and private label

Private-label retailers can compete without reproducing the Mucinex name. The most commercially attractive products are likely to be:

• Guaifenesin ER tablets.
• Guaifenesin plus dextromethorphan tablets.
• Sugar-free liquids.
• Multi-symptom cold products.
• Small-format or easy-swallow tablets.

Excipient suppliers that can reduce manufacturing cost while preserving dissolution performance are positioned to benefit from private-label expansion.

Which companies are challenging or competing with Mucinex?

Mucinex competes across three groups:

Competitor group	Examples	Competitive basis
National cough and cold brands	Robitussin, Delsym, Vicks, Theraflu	Brand recognition and combination products
Retail private labels	CVS Health, Walgreens, Walmart, Costco and other store brands	Price and shelf placement
Generic manufacturers	Perrigo, Dr. Reddy's, Teva, Padagis and other OTC suppliers	Low-cost equivalent products

The competitive set varies by product. Delsym is more directly relevant to dextromethorphan antitussive positioning, while Robitussin competes across guaifenesin liquids and combination products. Private-label products present the most direct pricing pressure for guaifenesin tablets and liquids.

How does Mucinex compare with competing respiratory products?

Attribute	Mucinex	Robitussin	Delsym	Private-label guaifenesin
Core positioning	Mucus relief and expectoration	Broad cough and cold relief	Long-acting cough suppression	Value-oriented symptom relief
Main technical asset	Guaifenesin extended release	Liquid and combination platforms	Extended-release dextromethorphan	Cost-efficient dosage forms
Excipient opportunity	Release control and swallowability	Taste masking and suspension stability	Controlled-release antitussive matrix	Low-cost robust formulations
Brand vulnerability	Price substitution	Liquid taste and package competition	Ingredient-specific positioning	Limited brand loyalty
Patent dependence	Generally limited at active-ingredient level	Product-specific	Product-specific	Usually low

Mucinex has a stronger formulation story in extended-release expectorant tablets than in basic immediate-release liquids. Its commercial position is less defensible where products are differentiated only by flavor, bottle size, or label claims.

What FDA regulatory issues affect Mucinex excipient development?

Mucinex formulations must comply with the applicable OTC monograph or approved application, including active-ingredient concentration, labeling, dosage instructions, warnings, and dosage-form requirements.[1,5]

Excipient changes can trigger regulatory work when they affect:

• Dissolution or release characteristics.
• Bioavailability.
• Preservative effectiveness.
• Microbial quality.
• Dose uniformity.
• Stability.
• Organoleptic properties that influence dosing.
• Child-resistant packaging or measuring devices.

Excipients must be suitable for the intended route and dosage form. FDA’s Inactive Ingredient Database can support precedent analysis, but inclusion in the database does not establish automatic approval for every concentration or product type.[6]

For liquids, formulation developers must control pH, microbial growth, sedimentation, viscosity, and preservative compatibility. For tablets, the central quality attributes are dissolution, assay, content uniformity, hardness, friability, and stability.

What licensing opportunities exist in Mucinex excipients?

The most attractive licensing targets are platform technologies that can be applied across multiple Mucinex line extensions.

High-value licensing categories

1. Extended-release matrix technology
   A polymer platform that reduces tablet size while preserving a 12-hour release profile.

2. Taste-masked multiparticulates
   A technology applicable to pediatric liquids, chewables, and sprinkle-compatible products.

3. Sugar-free liquid systems
   A stable sweetener, viscosity, and preservative platform for guaifenesin and combination products.

4. Moisture-resistant packaging
   High-barrier blister and bottle systems that reduce dissolution drift during consumer use.

5. Combination-product separation technology
   Bilayer or coated-particle systems that improve compatibility between guaifenesin and dextromethorphan or other actives.

6. Easy-swallow tablet technology
   Tablet geometry, coatings, and excipient systems that reduce perceived size without lowering drug load.

License value would depend on demonstrable improvements in dissolution robustness, manufacturing yield, stability, sensory performance, or consumer adherence. A supplier that only provides a commodity polymer is more exposed to dual sourcing and price competition.

How strong is the Mucinex formulation estate?

The Mucinex formulation estate is commercially meaningful but likely narrower than the brand’s market visibility suggests. Its strongest elements are formulation know-how, process control, product appearance, and trademark protection.

Estate component	Relative strength
Guaifenesin active ingredient	Low
Basic tablet formulation	Low to moderate
Extended-release matrix	Moderate
Combination-product architecture	Moderate
Taste masking and pediatric delivery	Moderate
Manufacturing process know-how	Moderate
Trademark and trade dress	High for brand protection
OTC regulatory pathway	Moderate

The principal business risk is substitution by lower-priced guaifenesin products. The principal opportunity is to extend the brand into delivery formats that solve practical consumer problems rather than relying solely on additional active-ingredient combinations.

Key Takeaways

• Mucinex is primarily a guaifenesin brand with its strongest technical differentiation in extended-release tablets.
• The highest-value excipient opportunities are release-control polymers, smaller high-dose tablets, taste-masked liquids, sugar-free systems, and moisture-resistant packaging.
• Guaifenesin itself provides little meaningful active-ingredient patent protection.
• Brand, trademark, trade dress, formulation know-how, and retail distribution are more important than composition-of-matter exclusivity.
• Immediate-release and private-label products face the highest generic and price-substitution risk.
• Extended-release and combination products create stronger manufacturing and formulation barriers.
• Excipient suppliers should prioritize technologies that improve dissolution robustness, sensory performance, tablet size, stability, or manufacturing yield.
• Mucinex has no single patent-expiration or exclusivity-loss date because its product family includes multiple dosage forms and combinations.

FAQs

Does Mucinex use a special release-control excipient?

Mucinex extended-release tablets rely on a controlled-release matrix architecture. Public labeling identifies inactive ingredients but generally does not disclose the complete polymer grade, processing conditions, or manufacturing parameters.

Are guaifenesin generics a threat to Mucinex?

Yes. Generic and private-label guaifenesin products can compete directly on price. Extended-release tablets and combination products have higher technical barriers than immediate-release tablets and liquids.

Can an excipient supplier patent a better Mucinex formulation?

Yes. A supplier or manufacturer may seek patent protection for a new release-control matrix, taste-masking system, multiparticulate structure, tablet architecture, or manufacturing process if the invention meets applicable patentability standards.

What is the best pediatric opportunity for a Mucinex competitor?

Taste-masked, sugar-free, accurately dosed liquids and small chewable or mini-tablet formats offer the clearest opportunity. The formulation must maintain dose uniformity, palatability, microbial control, and stable viscosity.

Does Mucinex require biosimilar analysis?

No. Mucinex products are small-molecule OTC drug products, not biologics. Biosimilar analysis is not applicable. Generic-drug, OTC monograph, formulation, trademark, and retail-substitution analysis are the relevant frameworks.

References

1. U.S. Food and Drug Administration. (2024). Over-the-counter monograph M012: Cough, cold, allergy, bronchodilator, and antiasthmatic drug products. https://www.accessdata.fda.gov
2. DailyMed. (2024). Mucinex guaifenesin extended-release tablets: Drug label. National Library of Medicine. https://dailymed.nlm.nih.gov
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and patent certifications. https://www.fda.gov/drugs
5. Code of Federal Regulations. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov
6. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm